Primary Central Nervous System Lymphoma in Adults

A multidisciplinary team works together to provide you with personalized care for primary central nervous system lymphoma. This rare, fast-growing type of non-Hodgkin lymphoma can start in the brain, eyes, spinal cord, or meninges, which are the layers of tissue that cover and protect the brain and spinal cord. We use the newest genetic tests to determine what therapies are best for you. Your treatment plan may include chemotherapy, targeted drugs, and radiation therapy. You may also be eligible to participate in clinical trials, which offer access to promising new medications.

Clinical Trials and Research Studies

Phase 5

A Phase 1-2 First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Lymphomas.

Learn More

Phase 2

A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors

Learn More

Phase 2

A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas Cutaneous Squamous Cell Carcinoma Merkel Cell Carcinoma and Other Rare Skin Tumors

Learn More

Phase 1

A Phase 1 Study of TJ011133 Administered Alone or in Combination with Pembrolizumab or Rituximab in Subjects with Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Learn More